Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial

    VANCOUVER, Oct. 9 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced that it intends to file Premarket Notification 510(k) documents with
the U.S. Food and Drug Administration (FDA) for its innovative, anti-infective
5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC).
    "After reviewing the data from our recently completed clinical trial, we
are extremely pleased that the 5-FU CVC pivotal study has hit its primary
efficacy endpoint while showing an excellent safety profile. We are looking
forward to presenting the full data set in a scientific symposium at the
upcoming Critical Care Congress in February," said Dr. William Hunter,
President and CEO of Angiotech.
    "Based on the positive results from the U.S. pivotal trial, we will
prepare a 510(k) package, which we expect to submit to the FDA in the fourth
quarter of 2007. This is another important step towards commercializing our
5-FU CVC product line and our 5-FU anti-infective platform," continued Dr.
    "This is an exciting milestone for Angiotech. Our R&D efforts are
striving to address two of the most common problems in surgery and medical
devices: restenosis following vascular injury and infection related to medical
device implantation. We continue to work towards achieving success in one of
the most challenging areas of medical device development by deriving new and
useful applications for our leading drug platforms, paclitaxel and 5-FU, and
taking them from their early stages in the lab to their actual clinical use,"
added Dr. Jeff Walker, Senior VP, Research and Development for Angiotech.
    The 5-FU CVC is expected to be Angiotech's first product line to be
completely researched, developed and commercialized using internal resources,
personnel and technologies, many of which were obtained through previous
acquisitions completed by Angiotech.
    In July 2007, Angiotech completed enrolment of 960 patients in the
clinical trial of its 5-FU CVC, which was one of the largest CVC studies ever
conducted. Designed as a randomized, single-blind, active-controlled, two-arm,
multi-center clinical study, the primary objective is to compare the Angiotech
5-FU CVC to a leading anti-infective catheter with regards to preventing
bacterial colonization.
    Angiotech plans to present the 5-FU CVC pivotal study results at the
"37th Critical Care Congress" hosted by the Society of Critical Care Medicine,
which will be held on February 2-6, 2008 at the Hawaii Convention Center.
    Pending the receipt of all necessary regulatory approvals, Angiotech
anticipates launching the commercial 5-FU CVC product line in 2008.

    About Central Venous Catheters (CVC)

    Central venous catheters (CVC) are usually inserted into critically ill
patients for extended periods of time to administer fluids, drugs, and
nutrition, as well as facilitate frequent blood draws. One of the
complications associated with CVC implantation is infection, which can occur
when bacteria contaminate the catheter. CVC infections that progress to
bloodstream infections, or septicemia, can become life threatening.

    About Catheter-Related Infections

    In the U.S., the cost per catheter-related infection can range from
$3,700 to $29,000(1). In addition, the Centers for Disease Control and
Prevention (CDC) has raised concerns about the overuse of traditional
antibiotics, which can contribute to an increase in the antibiotic resistance
of bacteria.

    About Angiotech's 5-FU CVC

    Angiotech believes that 5-FU, a well-known and approved compound, has the
potential to be used as a coating to prevent catheter-related infections as
effectively as traditional antiseptics and antibiotics. In addition, since
5-FU has no clinical application as either a systemic antibiotic or a hospital
antiseptic, there is little risk to the hospital or the community at-large of
creating a "super-bug" that is resistant to a useful class of antibiotic and
can make infection control more complex.
    The principle behind using 5-FU on a CVC is that the drug appears to
effectively interrupt the colonization of an implanted medical device by those
micro-organisms that typically gain entrance to the bloodstream via the local
skin penetration of implanted catheters. This reduction in colonization by
bacteria may have a net effect of reducing biofilm burden on the implanted
catheters, making them less likely to serve as reservoirs for additional

    Note on Forward Looking Statements

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and constitute "forward-looking information"
within the meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements may involve, but are not limited to,
comments with respect to our objectives and priorities for 2007 and beyond,
our strategies or future actions, our targets, our estimation of potential
market size, expectations for our financial condition and the results of, or
outlook for, our operations, research development and further product and drug
development. Such forward-looking statements also involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements. Such factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others, the
following: general economic and business conditions, both nationally and in
the regions in which we operate; technological changes that impact our
existing products or our ability to develop and commercialize future products;
competition; changes in business strategy or development plans; the ability to
attract and retain qualified personnel; existing governmental regulations and
changes in, or the failure to comply with, governmental regulations; adverse
results or unexpected delays in drug discovery and clinical development
processes; failure to obtain patent protection for discoveries; loss of patent
protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by third
parties; dependence upon, and relationships with strategic alliance partners
to develop and commercialize products and services based on our work; our
ability to obtain rights to technology from licensors; liability for patent
claims and other claims asserted against us; the requirement for substantial
funding to conduct research and development and to expand commercialization
activities or consummate acquisitions; the size of the market and the
potential market for our products in specific disease areas, other factors
referenced in our annual information form and other filings with the
applicable Canadian securities regulatory authorities or the Securities and
Exchange Commission; and any other factors that may affect performance. In
addition, our business is subject to certain operating risks that may cause
the actual results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These operating
risks include: our ability to successfully complete preclinical and clinical
development of our products; the ability to obtain and enforce timely patent
and other intellectual property protection for our technology and products;
decisions, and the timing of decisions, made by health regulatory agencies
regarding approval of our technology and products; the ability to complete and
maintain corporate alliances relating to the development and commercialization
of our technology and products; market acceptance of our technology and
products; the competitive environment and impact of technological change; the
continued availability of capital to finance our activities; our ability to
integrate into our business the operations of AMI; and, our ability to achieve
the operational and other synergies and the other commercial or financial
benefits expected as a result of the acquisition of AMI. Given these
uncertainties, assumptions and risk factors, readers are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained in this
report to reflect future results, events or developments.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

    (1) Mermel, LA. Prevention of intravascular catheter-related infections.
    Ann Intern Med. 2000; 132:391-402.

For further information:

For further information: Jodi Regts, Senior Manager, Investor Relations
and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930,; Analysts and Investors: Deirdre Neary, Manager, Investor
Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890